Cost-Effectiveness of Disease- Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
3
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
4
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
5